Compare MLR & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLR | EBS |
|---|---|---|
| Founded | 1990 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.9M | 595.6M |
| IPO Year | 2004 | 2006 |
| Metric | MLR | EBS |
|---|---|---|
| Price | $41.87 | $8.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $55.00 | $15.00 |
| AVG Volume (30 Days) | 34.7K | ★ 588.6K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | 7.89 | ★ 125.83 |
| EPS | ★ 1.68 | 0.93 |
| Revenue | ★ $1,257,500,000.00 | $742,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.03 | $15.21 |
| P/E Ratio | $25.26 | ★ $5.92 |
| Revenue Growth | ★ 9.03 | N/A |
| 52 Week Low | $33.81 | $4.02 |
| 52 Week High | $58.49 | $14.06 |
| Indicator | MLR | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 21.44 |
| Support Level | $41.82 | $7.51 |
| Resistance Level | $43.00 | $9.68 |
| Average True Range (ATR) | 1.26 | 0.55 |
| MACD | -0.34 | -0.14 |
| Stochastic Oscillator | 20.08 | 4.48 |
Miller Industries Inc is engaged in the manufacturing of vehicle towing and recovery equipment. The company produces wreckers, car carriers, and trailer bodies under the Century, Vulcan, Challenger, Holmes, Champion, Chevron, Eagle, Titan, Jige, and Boniface brands. The products are sold in North America, Canada, and Mexico through independent distributors.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.